He describes tirzepatide acting on appetite hormones and cites a 72-week trial where adults without diabetes lost an average 15% to 21% of weight, depending on dose.
Recap by typeshit. Post by Dr. Rafi on X.
Avi Roy points out that the largest test so far found no memory benefit from the drug in Ozempic, despite hopes raised by health record studies.
Balwinder Singh and Raman Baweja link GLP-1 use to less kidney replacement therapy in bipolar patients with CKD, and flag lithium toxicity cases.
Yale Medicine says 5% to 10% of people on GLP-1 weight loss drugs see little result, and points to diet as one factor that can blunt the effect.
24:26
A doctor's explainer sorting peptides into eight broad categories. An evergreen overview for anyone still learning the basics.
A short post from Hany Ragy on trypanophobia and the pill form of Wegovy, linking out for more on why needle-averse patients may lean toward oral semaglutide.
A Commons health committee report finds only about 6% of eligible patients will get Mounjaro on the NHS in three years, while most UK GLP-1 packs are bought privately.
Loading…